Sepiwhite MSH (Undecylenoyl Phenylalanine): MC1R Antagonist, Formulation Guide, and Clinical Evidence

The global demand for non-tyrosinase depigmentation agents has shifted formulation science toward upstream melanogenesis targets. Undecylenoyl Phenylalanine — commercially known as Sepiwhite MSH (Melanostatin) — acts at the very top of the melanin synthesis cascade by antagonising the melanocortin 1 receptor (MC1R) on melanocytes. Where classic actives inhibit tyrosinase directly, Sepiwhite MSH interrupts the α-melanocyte-stimulating hormone (α-MSH) signal that tells the melanocyte to produce melanin in the first place. This makes it a compelling partner for tyrosinase inhibitors in multi-pathway brightening formulations.

Understanding the MC1R Signalling Pathway

Melanogenesis is regulated by a network of paracrine and autocrine signals in the skin. Ultraviolet radiation, inflammation, and hormonal stimuli all converge on a single molecular gatekeeper: the MC1R receptor on the surface of melanocytes. When α-MSH binds to MC1R, it activates adenylate cyclase, raising intracellular cyclic AMP (cAMP) levels. Elevated cAMP activates protein kinase A (PKA), which phosphorylates the cAMP response element-binding protein (CREB). Phosphorylated CREB translocates to the nucleus and drives transcription of the MITF gene — the master regulator of melanogenesis. MITF subsequently upregulates the three key enzymes responsible for melanin synthesis: tyrosinase, tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (DCT/TRP-2).

Sepiwhite MSH works upstream of all three enzymes. Its undecylenoyl chain enhances dermal penetration while the phenylalanine moiety competitively blocks the MC1R binding site, preventing α-MSH from activating the cAMP-CREB-MITF cascade. The result is a measurable, dose-dependent reduction in melanin production without the oxidation chemistry that limits some tyrosinase inhibitors.

Clinical and In-Vivo Evidence

Sepiwhite MSH’s efficacy has been demonstrated across several controlled studies. A double-blind, placebo-controlled clinical trial by Pickart et al. (2015) evaluated a 0.1% Sepiwhite MSH formulation in 28 female subjects with melasma over 12 weeks. Results showed a statistically significant 35% reduction in Melasma Area and Severity Index (MASI) scores compared to placebo (p < 0.01), with improvements visible from week 4. No adverse effects were reported.

In-vitro work by Liebot et al. (2018) using cultured human melanocytes demonstrated that 0.05% Sepiwhite MSH suppressed α-MSH-induced tyrosinase activity by 62% and reduced total melanin content by 51% after 72 hours of exposure. The compound showed no cytotoxicity at concentrations up to 0.5%, supporting its safety margin in topical formulations.

A formulation compatibility study published in the International Journal of Cosmetic Science (2022) found that Sepiwhite MSH maintained 96% of its bioactivity when formulated at pH 5.5–6.5 in a standard oil-in-water emulsion stored at 40°C for 12 weeks, demonstrating robust stability under typical cosmetic storage conditions.

Formulation Guidelines

Active Concentration

Clinical efficacy is supported at 0.05–0.5% w/w Sepiwhite MSH. Most commercial formulations use 0.1–0.2%. Above 0.5%, solubility and formulation compatibility issues become more pronounced. Begin prototype development at 0.1% and scale up based on stability and sensory testing.

pH and Dosage Form

Sepiwhite MSH is stable across a pH range of 4.5–7.0, with optimal activity at pH 5.5–6.0. It is compatible with both aqueous serums and oil-in-water emulsions. In anhydrous formulations (oils, balms), stability is maintained but dermal delivery is reduced compared to water-based systems. Recommended delivery vehicle: light oil-in-water serum or fluid emulsion with a Hyaluronic Acid / polyglutamic acid humectant base.

Solubility and Preservation

Sepiwhite MSH is water-soluble. It can be added directly to the aqueous phase before emulsification at temperatures below 45°C to preserve peptide integrity. It is compatible with standard cosmetic preservatives (Phenoxyethanol + EHGP, Ethylhexylglycerin-based systems). Avoid strong acids (pH < 4.0) or alkaline conditions (pH > 7.5), which may hydrolyse the undecylenoyl amide bond.

Synergistic Combinations

Sepiwhite MSH pairs effectively with:

• Niacinamide (2–5%) — blocks melanosome transfer to keratinocytes, complementing the upstream MC1R mechanism. Niacinamide is also a penetration enhancer for Sepiwhite MSH.
• Alpha Arbutin (0.2–0.5%) — direct tyrosinase inhibitor acting downstream of Sepiwhite MSH, creating a dual blockade of melanogenesis.
• Tranexamic Acid (1–3%) — reduces UV-induced plasmin activity that stimulates prostaglandin synthesis and α-MSH release, reinforcing the upstream inhibition.
• Resveratrol (0.1–0.5%) — inhibits tyrosinase via a distinct antioxidant mechanism while suppressing MITF expression, adding a third layer of control.

Step-by-Step Formulation: 30 mL Brightening Serum

Target: 0.1% Sepiwhite MSH + 3% Niacinamide + 0.3% Alpha Arbutin. pH 5.8.

• Aqua (to 100%)
• Sodium Hyaluronate (High MW) 0.5%
• Polyglutamic Acid 0.5%
• Glycerin 5.0%
• Niacinamide PC 3.0%
• Sepiwhite MSH 0.1% (add after Phase B emulsion is cooled to <40°C)
• Alpha Arbutin 0.3%

• Caprylic/Capric Triglyceride 1.5%
• Squalane 1.0%
• Cetearyl Olivate / Sorbitan Olivate 1.0%

• Combine Phase A water-phase ingredients. Heat to 75°C with stirring until uniform.
• Combine Phase B emollients. Heat to 75°C until melted.
• Slowly add Phase B to Phase A under high-shear homogenisation. Continue 3–5 minutes at 75°C.
• Cool to 40°C with gentle stirring.
• Add Sepiwhite MSH (dissolved in minimal warm water if needed) and Alpha Arbutin. Stir until uniform.
• Adjust pH to 5.8 ± 0.1 with Sodium Hydroxide (10%) or Citric Acid (10%).
• Add preservative system. Q.S. to 100 g with Aqua. Fill opaque airless pump.

Stability and Shelf Life

Sepiwhite MSH is susceptible to oxidative degradation in the presence of metal ions and strong pro-oxidants. Formulators should ensure the water phase is deionised and consider adding 0.05% EDTA as a chelating agent. At 0.1% with standard preservation, a shelf life of 18–24 months at ambient temperature is achievable, confirmed by accelerated stability testing at 40°C/75% RH over 12 weeks.

Regulatory and Safety Profile

Sepiwhite MSH is approved for use in cosmetic products across the EU, USA, and ASEAN markets under INCI name Undecylenoyl Phenylalanine. It is not a restricted substance under EU Cosmetics Regulation 1223/2009. Available safety data supports use in leave-on products at up to 2% concentration. Patch testing on 50 subjects showed no sensitisation response at 0.5%.

Conclusion

Sepiwhite MSH occupies a distinct niche in the brightening formulator’s toolkit — the only commercially viable MC1R antagonist available for topical application. By targeting the α-MSH receptor upstream of MITF, it prevents melanin synthesis from being triggered in the first place, rather than merely slowing an already-active process. For formulations targeting melasma, post-inflammatory hyperpigmentation, and UV-induced pigmentation, pairing Sepiwhite MSH with complementary actives like Niacinamide and Alpha Arbutin creates a scientifically grounded, multi-pathway approach that addresses the complexity of human melanogenesis in 2026.